<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471636</url>
  </required_header>
  <id_info>
    <org_study_id>20-448</org_study_id>
    <nct_id>NCT04471636</nct_id>
  </id_info>
  <brief_title>Telemedicine in Outpatient Covid-19 Patients</brief_title>
  <acronym>MR SPOC</acronym>
  <official_title>Munich Remote SpO2 and Electrocardiogram Assessment in Covid-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Referat für Gesundheit und Umwelt (RGU), Landeshauptstadt München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Covid-19, a commonly severe respiratory tract infection caused by the SARS-CoV2 Coronavirus,&#xD;
      poses an increasing threat to individual health and health care systems. The individual&#xD;
      disease course ranges from mild to life threatening, the pandemic spread leads to a shortage&#xD;
      of health care resources including intensive care availability. It should be the overarching&#xD;
      goal to allocate sparse health care resources to those most at need and to simultaneously&#xD;
      avoid unnecessary blocking of resources by clinically unjustified hospitalizations.&#xD;
&#xD;
      Individuals with preexisting cardiovascular conditions are at the highest risk of health&#xD;
      deterioration, even at younger age. Objective criteria for hospitalization are not&#xD;
      immediately available in a outpatient settings. Hence, hospitalization and emergency medical&#xD;
      contact is often triggered by subjectively interpreted symptoms. The goal of this project is&#xD;
      thus to improve the availability of objective measurements in the outpatient setting by means&#xD;
      of an innovative, smartwatch mediated telemedicine approach.&#xD;
&#xD;
      To achieve this goal, the investigators will conduct a randomized clinical trial comparing a&#xD;
      smartwatch based telemedicine intervention with standard of care. The intervention group will&#xD;
      receive regular objective measurements of heart rate, ECG, and SpO2 and will get access to a&#xD;
      24/7 medical care hotline for consultation. The investigators hypothesize that the&#xD;
      intervention group will benefit by a significant reduction in unnecessary hospitalizations&#xD;
      and unplanned emergency medicine contacts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participants with a combination of hospitalization and unplanned use of hospital emergency department or emergency medical service</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of any of the above during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants hospitalized</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of hospitalization during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with unplanned use of hospital emergency department or emergency medical service</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of any of the above during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants experiencing death of any cause</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of death of any cause during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants experiencing death of Covid-19</measure>
    <time_frame>30 days</time_frame>
    <description>Occurence of daeth of Covid-19 during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid-19</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Telemedicine Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Withings ScanWatch</intervention_name>
    <description>The smart watch is capable of recording SpO2, ECG, and heart rate.</description>
    <arm_group_label>Telemedicine Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed SARS-CoV2 infection and clinical Covid-19 disease&#xD;
&#xD;
          -  age ≥40 and &lt;60 years&#xD;
&#xD;
          -  Presence of ≥1 relevan cardiovascular condition, defined as (or):&#xD;
&#xD;
               -  atrial fibrillation&#xD;
&#xD;
               -  systolic or diastolic heart failure&#xD;
&#xD;
               -  LV ejection fraction &lt;50%&#xD;
&#xD;
               -  coronary artery disease with past PCI or CABG&#xD;
&#xD;
               -  Past myocardial infarction&#xD;
&#xD;
               -  diabetes mellitus&#xD;
&#xD;
               -  arterial hypertension (treated or untreated)&#xD;
&#xD;
               -  active smoking&#xD;
&#xD;
          -  availability of smartphone and sufficient internet connectivity at home&#xD;
&#xD;
          -  ability to use smartwatch&#xD;
&#xD;
          -  informed consent to study participation and data protection concept&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in concurrent clinical trial&#xD;
&#xD;
          -  indication for hospitalization at study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department Head</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moritz F Sinner, MD, MPH</last_name>
    <phone>+49-89-4400-76159</phone>
    <email>msinner@med.lmu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Kääb, MD, PhD</last_name>
    <phone>+49-89-4400-72300</phone>
    <email>skaab@med.lmu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LMU Klinikum</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz F Sinner, MD, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Moritz F. Sinner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV2</keyword>
  <keyword>Covid-19</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>telemedicine</keyword>
  <keyword>ECG</keyword>
  <keyword>SpO2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

